Literature DB >> 1097109

Quantitative immunofluorescence studies of the tumor antigen-bearing cell in giant cell tumor of bone and osteogenic sarcoma.

V S Byers, A S Levin, J O Johnston, A J Hackett.   

Abstract

Tumor-associated antigen was found by reacting sera from two patients with giant cell tumor of bone with cells derived from their tumors, using autologous serum as intermediate reactant and fluorescein-conjugated goat anti-human IgG as final reactant. Approximately 40% of the plump, spindle-shaped cells that formed the background stroma of these tumors possessed the antigen; however, it was not present on giant cells. Fluorescence was much greater than that on similarly stained cells from 4 osteogenic sarcomas, suggesting that the antigenic density on cells from giant cell tumor was greater than that on cells from osteogenic sarcoma. Antibodies in sera from giant cell tumor patients and osteogenic sarcoma patients showed specific cross-reactivity. Stromal cells of giant cell tumors were established in culture and retained tumor-associated antigen, whereas giant cells failed to divide and detached from the flask within two weeks. Intensity of fluorescence (antigenic density) decreased with progressive passage levels, but a larger percentage of cells showed fluorescence. At the tenth passage, all cells bore tumor-associated antigen. Cultured cells that were injected s.c. into mice formed progressively growing nodules, the cells of which were morphologically indistinguishable from stromal cells of the original tumor; all cells retained tumor-associated antigen, but antigenic density had decreased to about one-seventh of the value found originally. No giant cells were present in the nodules.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1097109

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Human giant cell tumors of bone identification and characterization of cell types.

Authors:  S R Goldring; M S Roelke; K K Petrison; A K Bhan
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

2.  In vitro studies of poison oak immunity. I. In vitro reaction of human lymphocytes to urushiol.

Authors:  V S Byers; W L Epstein; N Castagnoli; H Baer
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

3.  Delineation of four cell types comprising the giant cell tumor of bone. Expression of Ia and monocyte-macrophage lineage antigens.

Authors:  G R Burmester; R J Winchester; A Dimitriu-Bona; M Klein; G Steiner; H A Sissons
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

4.  Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction.

Authors:  A H Gorn; S M Rudolph; M R Flannery; C C Morton; S Weremowicz; T Z Wang; S M Krane; S R Goldring
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

Review 5.  Giant Cell Tumor of Bone: An Update.

Authors:  Atrayee Basu Mallick; Sant P Chawla
Journal:  Curr Oncol Rep       Date:  2021-03-22       Impact factor: 5.075

Review 6.  Giant-cell tumor of bone: treatment options and role of denosumab.

Authors:  Arun S Singh; Neal S Chawla; Sant P Chawla
Journal:  Biologics       Date:  2015-07-14

Review 7.  Giant cell tumour of bone: new treatments in development.

Authors:  A López-Pousa; J Martín Broto; T Garrido; J Vázquez
Journal:  Clin Transl Oncol       Date:  2015-01-24       Impact factor: 3.405

8.  Giant-cell tumour of bone: cytological studies.

Authors:  K Kasahara; T Yamamuro; A Kasahara
Journal:  Br J Cancer       Date:  1979-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.